- Home
- CHRS vs TROO Comparison
CHRS vs TROO Comparison
Compare CHRS & TROO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- TROO
- Stock Information
- Founded
- CHRS 2010
- TROO 2005
- Country
- CHRS United States
- TROO Hong Kong
- Employees
- CHRS N/A
- TROO N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- TROO Radio And Television Broadcasting And Communications Equipment
- Sector
- CHRS Health Care
- TROO Technology
- Exchange
- CHRS Nasdaq
- TROO Nasdaq
- Market Cap
- CHRS 191.3M
- TROO 214.9M
- IPO Year
- CHRS 2014
- TROO N/A
- Fundamental
- Price
- CHRS $1.32
- TROO $1.79
- Analyst Decision
- CHRS Strong Buy
- TROO
- Analyst Count
- CHRS 4
- TROO 0
- Target Price
- CHRS $5.38
- TROO N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- TROO 317.1K
- Earning Date
- CHRS 03-12-2025
- TROO 11-15-2024
- Dividend Yield
- CHRS N/A
- TROO N/A
- EPS Growth
- CHRS N/A
- TROO N/A
- EPS
- CHRS N/A
- TROO N/A
- Revenue
- CHRS $304,340,000.00
- TROO $4,344,000.00
- Revenue This Year
- CHRS $2.47
- TROO N/A
- Revenue Next Year
- CHRS N/A
- TROO N/A
- P/E Ratio
- CHRS N/A
- TROO N/A
- Revenue Growth
- CHRS 44.19
- TROO 14.77
- 52 Week Low
- CHRS $0.66
- TROO $0.73
- 52 Week High
- CHRS $2.87
- TROO $4.89
- Technical
- Relative Strength Index (RSI)
- CHRS 41.91
- TROO 49.21
- Support Level
- CHRS $1.38
- TROO $1.60
- Resistance Level
- CHRS $1.60
- TROO $2.19
- Average True Range (ATR)
- CHRS 0.12
- TROO 0.20
- MACD
- CHRS -0.03
- TROO 0.01
- Stochastic Oscillator
- CHRS 1.10
- TROO 36.51
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.